We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

HTG Introduces Testing Method for RNA in Fixed Tissue Samples

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

HTG, Inc. has announced the availability of a new in situ testing method for gene expression in formalin-fixed, paraffin-embedded (FFPE) tissue samples.

Using HTG’s qNPA™ (quantitative Nuclease Protection Assay) technology, researchers can quantitate RNA expression for up to 16 targets simultaneously in FFPE tissue sections without the need for extraction or target amplification.

With conventional methods it has been challenging for researchers to analyze fixed tissue samples and yield useful information because it is difficult to extract RNA from fixed sample blocks for several reasons.

Formalin, the most common fixative, is excellent at preserving structure but the fixation process also causes a series of crosslinks to form, making molecular assays difficult to run.

Second, the quality of RNA quickly deteriorates over time. Both factors make it difficult to extract gene targets for molecular testing, secure accurate information and eliminate false positives.

HTG’s qNPA technology allows researchers to simply lyse the tissue section, incubate the qNPA probes and then detect the levels of up to 16 different RNA targets simultaneously.

Whole assay CVs are 10 percent or less and the qNPA method has been tested successfully on tissue blocks up to 15 years old making retrospective studies feasible.

The ArrayPlate qNPA technology provides the absolute sensitivity to measure any gene desired, including low abundant genes.

Instead of studying one gene at a time, researchers are also able to select a set of genes for simultaneous evaluation, a critical step in identifying the most promising drug compounds to treat complex, multi-factorial diseases.

“Until now, there has not been an effective means to analyze RNA in fixed tissue samples,” said Bruce Seligmann, CSO, HTG. “HTG’s qNPA multiplexed technology offers researchers a quick, easy and reliable method to examine RNA stored in fixed tissue samples.

HTG’s method is so sensitive and precise that the age of the tissue block is no longer a factor and retrospective studies can be performed to identify changes in diseases or patients over time.”